Comparative, pivotal, phase III trial of spray-on transdermally delivered testosterone [Testagen TDS] versus gel testosterone for male hormone replacement

Trial Profile

Comparative, pivotal, phase III trial of spray-on transdermally delivered testosterone [Testagen TDS] versus gel testosterone for male hormone replacement

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Testosterone (Primary) ; Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2016 According to a TransDermal Delivery Solutions media release, the Company has received regulatory approval for pivotal clinical trials of Testagen HypoSpray from the British National Health Services and the Medicine and Health Products Review Authority. The company expects to initiate this trial in next few weeks.
    • 26 Aug 2013 New trial record
    • 22 Aug 2013 Planned initiation date changed from 1 Mar 2009 to 1 Dec 2013, based on information in a Transdermal Delivery Solutions Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top